BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17591100)

  • 1. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer.
    Ikoma H; Ichikawa D; Daito I; Nobuyuki T; Koike H; Okamoto K; Ochiai T; Ueda Y; Yamagishi H; Otsuji E
    Hepatogastroenterology; 2007; 54(75):946-50. PubMed ID: 17591100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer.
    Ichikawa D; Koike H; Ikoma H; Ikoma D; Tani N; Otsuji E; Kitamura K; Yamagishi H
    Anticancer Res; 2004; 24(4):2477-81. PubMed ID: 15330201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between serum DNA methylation and prognosis in gastric cancer patients.
    Ikoma H; Ichikawa D; Koike H; Ikoma D; Tani N; Okamoto K; Ochiai T; Ueda Y; Otsuji E; Yamagishi H
    Anticancer Res; 2006; 26(3B):2313-6. PubMed ID: 16821608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An early detection of recurrence using reverse transcriptase-polymerase chain reaction (RT-PCR) and methylation-specific polymerase chain reaction (MSP) from peripheral blood in patients after gastrectomy].
    Tani N; Ichikawa D; Ikoma D; Ikoma H; Sai S; Tomita H; Okamoto K; Kikuchi S; Fujiwara H; Ochiai T; Ueda Y; Otsuji E; Hagiwara A; Yamagishi H
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1720-2. PubMed ID: 17212086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of serum aberrant methylation and conventional tumor markers in gastric cancer patients.
    Koike H; Ichikawa D; Ikoma H; Tani N; Ikoma D; Otsuji E; Okamoto K; Ueda Y; Kitamura K; Yamagishi H
    Hepatogastroenterology; 2005; 52(64):1293-6. PubMed ID: 16001680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients.
    Koike H; Ichikawa D; Ikoma H; Otsuji E; Kitamura K; Yamagishi H
    J Surg Oncol; 2004 Sep; 87(4):182-6. PubMed ID: 15334633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
    Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
    Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cells and aberrant methylation as tumor markers in patients with esophageal cancer.
    Ikoma D; Ichikawa D; Ueda Y; Tani N; Tomita H; Sai S; Kikuchi S; Fujiwara H; Otsuji E; Yamagishi H
    Anticancer Res; 2007; 27(1B):535-9. PubMed ID: 17348438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
    Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
    J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
    Kim YT; Lee SH; Sung SW; Kim JH
    Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
    Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D
    Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients.
    Nakayama G; Hibi K; Nakayama H; Kodera Y; Ito K; Akiyama S; Nakao A
    Anticancer Res; 2007; 27(3B):1459-63. PubMed ID: 17595762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of free tumor-related DNA in the serum of breast cancer patients].
    Zhang JJ; Ouyang T; Wan WH; Deng GR
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma.
    Lee TL; Leung WK; Chan MW; Ng EK; Tong JH; Lo KW; Chung SC; Sung JJ; To KF
    Clin Cancer Res; 2002 Jun; 8(6):1761-6. PubMed ID: 12060614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARĪ²2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
    Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
    Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
    J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
    Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H
    Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
    Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
    J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.